Table 3.

Characteristics of CGTG-102–treated patients

All CGTG-102 patients (n = 115)Single (n = 72)Serial all (n = 51)Serial incl. CGTG-102 (n = 22)Serial only CGTG-102 (n = 29)
SexNo. of patientsNo. of patientsNo. of patientsNo. of patientsNo. of patients
 Male43 (37%)29 (40%)15 (29%)8 (36%)7 (24%)
 Female72 (63%)43 (60%)36 (71%)14 (64%)22 (76%)
Age, y
 Median5859575956
 Range7–787–789–789–7135–78
WHO performance status
 0149835
 15635261511
 2392316313
 365110
Tumor type
 Ovarian cancera23141037
 Breast cancera16413b5b8
 Sarcomaa1511752
 Lung cancera104725
 Melanoma9722
 Colon or rectal cancer7611
 Mesotheliomaa64321
 Gastric or esophageal55
 Pancreatic cancera54211
 Renal cancer44c
 Cholangiocarcinoma43c11
 Head & neck cancer3211
 Prostate cancer312b2b-
 Thyroid cancer2111-
 Endometrial cancer11---
 Neuroblastoma11---
 Neuroendocrine (adrenal) cancer1-1-1
 Parotic cancer1-1-1
 Wilms tumor11---
Previous Treatments
 Surgery7544351421
 Chemotherapy11472502129
 Median of regimens (range)4 (0–14)3 (1–10)4 (0–14)4 (0–11)5 (1–14)
 Radiotherapy5530281216
 Stem Cell Transplantation11---
  • aEight patients are reported in both groups.

  • bOne patient having both breast and prostate cancer.

  • cOne patient having both cholangio and renal cancer.